77108 Federal Register / Vol. 88, No. 215 / Wednesday, November 8, 2023 / Notices 

Sunshine Act, 5 U.S.C. 552(b). In 

accordance with Commission policy, 

subject matter listed above, not disposed 

of at the scheduled meeting, may be 

carried over to the agenda of the 

following meeting. 

By order of the Commission. 

Issued: November 6, 2023. 

Sharon Bellamy, 

Supervisory Hearings and Information 

Officer. 

[FR Doc. 2023–24812 Filed 11–6–23; 11:15 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1287] 

Importer of Controlled Substances 

Application: Noramco 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Noramco has applied to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to SUPPLEMENTARY INFORMATION

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before December 8, 2023. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 8, 2023. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on October 4, 2023, 

Noramco, 500 Swedes Landing Road, 

Wilmington, Delaware 19801–4417, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled 

substance 

Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Marihuana ....................... 7360 I 

Tetrahydrocannabinols ... 7370 I 

Nabilone ......................... 7379 II 

Phenylacetone ................ 8501 II 

Opium, Raw .................... 9600 II 

Opium Extracts ............... 9610 II 

Opium Fluid Extract ........ 9620 II 

Opium Tincture ............... 9630 II 

Opium Powdered ............ 9639 II 

Opium Granulated .......... 9640 II 

Opium Poppy/Poppy 

Straw.

9650 II 

Noroxymorphone ............ 9668 II 

Poppy Straw Concentrate.9670 II 

Tapentadol ...................... 9780 II 

The company plans to import 

Phenylacetone (8501), and Poppy Straw 

Concentrate (9670) to bulk manufacture 

other controlled substances for 

distribution to its customers. The 

company plans to import an 

intermediate form of Tapentadol (9780) 

to bulk manufacture Tapentadol for 

distribution to its customers. In 

reference to drug codes 7360 

(Marihuana) and 7370 

(Tetrahydrocannabinols), the company 

plans to import a synthetic cannabidiol 

and a synthetic Tetrahydrocannabinol. 

No other activity for these drug codes is 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–24614 Filed 11–7–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1286] 

Bulk Manufacturer of Controlled 

Substances Application: Noramco 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Noramco has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before January 8, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 8, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on October 04, 2023, 

Noramco, 500 Swedes Landing Road, 

Wilmington, Delaware 19801–4417, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled 

substance 

Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Marihuana ....................... 7360 I 

Tetrahydrocannabinols ... 7370 I 

Codeine-N-oxide ............. 9053 I 

Dihydromorphine ............ 9145 I 

Hydromorphinol .............. 9301 I 

Morphine-N-oxide ........... 9307 I 

Amphetamine ................. 1100 II 

Lisdexamfetamine .......... 1205 II 

Methylphenidate ............. 1724 II 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 215 / Wednesday, November 8, 2023 / Notices 77109 

Controlled 

substance 

Drug 

code Schedule 

Nabilone ......................... 7379 II 

Phenylacetone ................ 8501 II 

Codeine .......................... 9050 II 

Dihydrocodeine ............... 9120 II 

Oxycodone ..................... 9143 II 

Hydromorphone .............. 9150 II 

Hydrocodone .................. 9193 II 

Morphine ......................... 9300 II 

Oripavine ........................ 9330 II 

Thebaine ......................... 9333 II 

Opium extracts ............... 9610 II 

Opium fluid extract ......... 9620 II 

Opium, tincture ............... 9630 II 

Opium, powdered ........... 9639 II 

Opium, granulated .......... 9640 II 

Oxymorphone ................. 9652 II 

Noroxymorphone ............ 9668 II 

Tapentadol ...................... 9780 II 

The company plans to bulk 

manufacture the listed controlled 

substances as an Active Pharmaceutical 

Ingredient for supply to its customers. 

In reference to drug codes 7360 

(Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–24613 Filed 11–7–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1291] 

Bulk Manufacturer of Controlled 

Substances Application: Curia 

Missouri, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Curia Missouri Inc. has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before January 8, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 8, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on August 3, 2023, Curia 

Missouri Inc., 2460 West Bennett Street, 

Springfield, Missouri 65807–1229, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled 

substance 

Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Amphetamine ................. 1100 II 

Lisdexamfetamine .......... 1205 II 

Methylphenidate ............. 1724 II 

Phenylacetone ................ 8501 II 

Tapentadol ...................... 9780 II 

The company plans to bulk 

manufacture the listed controlled 

substances for internal use 

intermediates or for sale to its 

customers. No other activities for these 

drug codes are authorized for this 

registration. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–24615 Filed 11–7–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

220th Meeting of the Advisory Council 

on Employee Welfare and Pension 

Benefit Plans; Notice of Meeting 

Pursuant to the authority contained in 

section 512 of the Employee Retirement 

Income Security Act of 1974 (ERISA), 29 

U.S.C. 1142, the 220th open meeting of 

the Advisory Council on Employee 

Welfare and Pension Benefit Plans (also 

known as the ERISA Advisory Council) 

will be held on December 11–12, 2023. 

On Monday, December 11, 2023, the 

meeting will begin at 1:00 p.m. and end 

at approximately 4:30 p.m. (ET). On 

Tuesday, December 12, 2023, the 

meeting will begin at 8:30 a.m. and end 

at approximately 3:00 p.m. (ET), with a 

break for lunch. 

The meeting will take place at the 

U.S. Department of Labor, 200 

Constitution Avenue NW, Washington, 

DC 20210 in Room 6, C5320. The 

meeting will also be accessible via 

videoconference and some participants, 

as well as members of the public, may 

elect to attend virtually. Instructions for 

public videoconference access will be 

available on the ERISA Advisory 

Council’s web page at https://

www.dol.gov/agencies/ebsa/about-ebsa/ 

about-us/erisa-advisory-council 

approximately one week prior to the 

meeting. 

The purpose of the open meeting is 

for Advisory Council members to 

finalize their observations and 

recommendations on the issues they 

studied in 2023, present their 

observations and recommendations to 

the Department of Labor, and receive an 

update from leadership of the Employee 

Benefits Security Administration 

(EBSA). 

The issues studied by the ERISA 

Advisory Council in 2023 are: (1) LongTerm Disability Benefits and Mental 

Health Disparity, and (2) Recordkeeping 

in the Electronic Age. Descriptions of 

these topics are available on the ERISA 

Advisory Council’s web page at https:// 

www.dol.gov/agencies/ebsa/about-ebsa/ 

about-us/erisa-advisory-council. 

Organizations or members of the 

public wishing to submit a written 

statement may do so on or before 

Monday, December 4, 2023, to Christine 

Donahue, Executive Secretary, ERISA 

Advisory Council. Statements should be 

transmitted electronically as an email 

attachment in text or pdf format to 

donahue.christine@dol.gov. Statements 

transmitted electronically that are 

included in the body of the email will 

not be accepted. Relevant statements 

received on or before Monday, 

December 4, 2023, will be included in 

the record of the meeting and made 

available through the EBSA Public 

Disclosure Room. No deletions, 

modifications, or redactions will be 

made to the statements received as they 

are public records. Warning: Do not 

include any personally identifiable or 

confidential business information that 

you do not want publicly disclosed. 

Individuals or representatives of 

organizations interested in addressing 

the ERISA Advisory Council at the 

public meeting must submit a written 

request to the Executive Secretary on or 

before Monday, December 4, 2023, via 

email to donahue.christine@dol.gov. 


lotter on DSK11XQN23PROD with NOTICES1